On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- Japan Approves Label Expansions for Rozlytrek, Alecensa and More
February 25, 2020
- MHLW Has to Decide Which Bureau Will Lead Formulary Push: Pharmacy Officer
February 21, 2020
- AMED to Fund Development of Coronavirus Diagnostics, Treatments, and Vaccines by NIID, Univ. of Tokyo
February 21, 2020
- Japan Panel to Review J-TEC’s Cell Product, Zolgensma on Feb. 26; Orphan Status for Luxturna Also Up for Discussion
February 20, 2020
- MHLW Looking to Build an “Integrated Pre- to Post-Marketing Assessment System”: Safety Division Chief
February 20, 2020
- MHLW Panel Backs Approval of Sakigake-Designated BNCT Radiation Therapy System
February 20, 2020
- 6 APIs Including Inebilizumab Designated as Orphan Drugs: MHLW
February 19, 2020
- Authorized Generics for Memary, Celecox among Approval List towards June Listing
February 18, 2020
- MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
February 18, 2020
- Japan OKs Edirol Generics towards June Listing, First Gx Entries for 13 Other Drugs Too
February 17, 2020
- Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
- MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
- Council Backs Public Knowledge-Based Application for Additional Indication for Novartis’ Sandostatin
February 14, 2020
- Enhertu, BNCT, Tepotinib and More Up for MHLW Panel Review; March Approval Eyed
February 13, 2020
- MHLW Calls for Stable Supplies of HIV Drugs amid Coronavirus Outbreak
February 13, 2020
- PMDA to Set Up New Consultation Services for Continuous Manufacturing, Database Use
February 12, 2020
- MHLW Urges Pharmacies to Limit Per-Customer Purchases for Face Masks, Sanitizer
February 12, 2020
- Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020
- Chuikyo OKs Supplementary Opinions for 2020 Reimbursement Reform; No Mention on Health Coverage Review
February 6, 2020
- AMED to Share Research Data to Tackle Wuhan Coronavirus
February 4, 2020
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…